Market Place
Sourcing Support
Halberd & Athena GTX Report Success of WatchDawg® PTSD Study
01 Oct 2024 //
GLOBENEWSWIRE
Halberd Partnership Gets Contract To Address Brain Injury And PTSD
11 Sep 2024 //
GLOBENEWSWIRE
Halberd Corp Issues Letter To Shareholders On WatchDawg
09 Sep 2024 //
GLOBENEWSWIRE
Halberd`s LDN+ Evolves To WatchDawg For Veteran Suicide
04 Sep 2024 //
GLOBENEWSWIRE
Halberd Corp. Issues Letter to Shareholders
26 Aug 2024 //
GLOBENEWSWIRE
Halberd`s TBI Mitigation Nasal Spray Shows Promising Phase II Results
24 Jul 2024 //
GLOBENEWSWIRE
Halberd/Athena GTX Research Promises a Much Brighter Future
22 May 2024 //
ACCESSWIRE
Halberd TBI Treatments Align With New US House Bill
09 May 2024 //
ACCESSWIRE
Halberd`s Patented Drug, LDN+ Trial Under the Four-Company CRADA Contract
04 Apr 2024 //
ACCESSWIRE
Halberd`s Top Executives Join Forces with Athena GTX CEO Mark Darrah
06 Feb 2024 //
ACCESSWIRE
Halberd Corporation 2023 Year-End CEO Update and 2024 Goals
11 Jan 2024 //
ACCESSWIRE
Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
10 Jan 2024 //
ACCESSWIRE
Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
09 Jan 2024 //
ACCESSWIRE
Halberd Corporation Signs Multi-Faceted Agreement with CrodenHealth.com
13 Dec 2023 //
ACCESSWIRE
Halberd Plans to Extend Research Partnership with Mississippi State University
15 Nov 2023 //
ACCESSWIRE
Halberd Corporation 2Q23 CEO Letter
20 Jul 2023 //
ACCESSWIRE
Halberd Initial Preclinical Testing Phase at MSU Complete
23 May 2023 //
ACCESSWIRE
Halberd Pre-Clinical Test Protocol Approved
09 May 2023 //
ACCESSWIRE
Halberd (HALB) Pursuing a Nasal Spray to Counteract the Effects of Head Trauma
02 May 2023 //
BUSINESSWIRE
Halberd Begins Preclinical Testing at Mississippi State University (MSU)
11 Apr 2023 //
ACCESSWIRE
Halberd`s Successful Meeting with CDC Leads to Expanded Testing of Antibiotic Resistant Pathogens
03 Apr 2023 //
ACCESSWIRE
Halberd and Mississippi State University (MSU) Sign Agreement
30 Mar 2023 //
ACCESSWIRE
Halberd Demonstrates Eradication of Multiple Strains of CDC
21 Feb 2023 //
ACCESSWIRE
Halberd Corporation Announces Breakthrough in Candida auris Treatment
13 Feb 2023 //
ACCESSWIRE
Halberd Demonstrates Eradication of CDC Provided Antibiotic Resistant Bacteria
08 Feb 2023 //
ACCESSWIRE
Halberd Conducts Animal Tests of Nasal Spray that Blocks Effects of Head Trauma
31 Jan 2023 //
ACCESSWIRE
Halberd Agrees to Animal Testing at Mississippi State University
24 Jan 2023 //
ACCESSWIRE
Halberd Receives Strains of Antibiotic Resistant Bacteria from CDC
06 Dec 2022 //
ACCESSWIRE
Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19
01 Dec 2022 //
ACCESSWIRE
Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19
30 Nov 2022 //
ACCESSWIRE
Halberd Signs DeveP and Marketing Agreement for Medications & Nutraceuticals
14 Nov 2022 //
ACCESSWIRE
